1.22Open1.22Pre Close0 Volume113 Open Interest150.00Strike Price0.00Turnover162.80%IV36.19%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry1.22Extrinsic Value100Contract SizeAmericanOptions Type-0.0417Delta0.0014Gamma191.11Leverage Ratio-0.2604Theta-0.0030Rho-7.97Eff Leverage0.0355Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet